Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
We must try to make the health care system more accessible for people with disabilities
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Subscribe To Our Newsletter & Stay Updated
